JP2019523001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523001A5 JP2019523001A5 JP2019503538A JP2019503538A JP2019523001A5 JP 2019523001 A5 JP2019523001 A5 JP 2019523001A5 JP 2019503538 A JP2019503538 A JP 2019503538A JP 2019503538 A JP2019503538 A JP 2019503538A JP 2019523001 A5 JP2019523001 A5 JP 2019523001A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- transduced
- culturing
- heterologous nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 77
- 108020004707 nucleic acids Proteins 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 44
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 238000012258 culturing Methods 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 25
- 102000004127 Cytokines Human genes 0.000 claims description 24
- 108090000695 Cytokines Proteins 0.000 claims description 24
- 108010002350 Interleukin-2 Proteins 0.000 claims description 19
- 102000000588 Interleukin-2 Human genes 0.000 claims description 19
- 239000013603 viral vector Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000004055 small Interfering RNA Substances 0.000 claims description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 8
- 230000002463 transducing effect Effects 0.000 claims description 8
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 7
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 6
- 102100030704 Interleukin-21 Human genes 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 230000003463 hyperproliferative effect Effects 0.000 claims description 6
- 108010074108 interleukin-21 Proteins 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 3
- -1 erbB2- Proteins 0.000 claims description 3
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims description 2
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100028801 Calsyntenin-1 Human genes 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 2
- 101150069255 KLRC1 gene Proteins 0.000 claims description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims description 2
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims description 2
- 102100035721 Syndecan-1 Human genes 0.000 claims description 2
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000003855 balanced salt solution Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366493P | 2016-07-25 | 2016-07-25 | |
| US62/366,493 | 2016-07-25 | ||
| PCT/US2017/043774 WO2018022646A1 (en) | 2016-07-25 | 2017-07-25 | Methods of producing modified natural killer cells and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523001A JP2019523001A (ja) | 2019-08-22 |
| JP2019523001A5 true JP2019523001A5 (enExample) | 2020-08-06 |
| JP7086928B2 JP7086928B2 (ja) | 2022-06-20 |
Family
ID=59656171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503538A Active JP7086928B2 (ja) | 2016-07-25 | 2017-07-25 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
| JP2020524196A Active JP7364559B2 (ja) | 2016-07-25 | 2018-11-01 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524196A Active JP7364559B2 (ja) | 2016-07-25 | 2018-11-01 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11293010B2 (enExample) |
| EP (2) | EP3487991B1 (enExample) |
| JP (2) | JP7086928B2 (enExample) |
| CN (2) | CN109844099B (enExample) |
| IL (1) | IL273979B2 (enExample) |
| SG (2) | SG11201810871WA (enExample) |
| WO (2) | WO2018022646A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| CN109844099B (zh) | 2016-07-25 | 2024-01-02 | 美国政府(由卫生和人类服务部的部长所代表) | 产生经修饰的自然杀伤细胞的方法及使用方法 |
| US20180344768A1 (en) * | 2016-12-09 | 2018-12-06 | Onkimmune Limited | Nk cell-based therapy |
| SG11201908337VA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| NZ766453A (en) | 2018-02-01 | 2022-02-25 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| PT3755347T (pt) * | 2018-02-21 | 2025-07-25 | Univ Texas | Células de apresentação de antigénio universais e utilizações destas |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| CN113518826A (zh) * | 2018-05-16 | 2021-10-19 | 全国儿童医院研究所 | 利用cas9核糖核蛋白来产生敲除的原代和扩增的人nk细胞 |
| CN112512573A (zh) * | 2018-05-23 | 2021-03-16 | 百提威生技股份有限公司 | 双特异性t细胞衔接蛋白及其用途 |
| WO2019229109A1 (en) * | 2018-05-30 | 2019-12-05 | Glycostem Therapeutics B.V. | Car nk cells |
| US20210230542A1 (en) * | 2018-06-06 | 2021-07-29 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for cell enrichment |
| IL296050B2 (en) | 2018-08-01 | 2024-12-01 | Immunitybio Inc | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
| SG11202102012SA (en) * | 2018-08-28 | 2021-04-29 | Pharos Vaccine Inc | Improved lentiviral vector |
| SG11202101996QA (en) * | 2018-08-28 | 2021-03-30 | Immunotech Biopharm Co Ltd | Improved therapeutic t cell |
| KR102839381B1 (ko) | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| CN110511912B (zh) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | 免疫细胞的功能调节 |
| AU2019357602A1 (en) * | 2018-10-10 | 2021-05-13 | Wisconsin Alumni Research Foundation | Kir 7.1 gene therapy vectors and methods of using the same |
| CN109402053A (zh) * | 2018-10-17 | 2019-03-01 | 广州元帅生物科技有限公司 | 一种外周血来源单个核细胞的分离及诱导培养方法 |
| US12410402B2 (en) * | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| CN113710691B (zh) * | 2019-02-20 | 2025-03-04 | 罗格斯新泽西州立大学 | 自然杀伤和嵌合抗原受体修饰的细胞的扩增 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020190771A1 (en) | 2019-03-15 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| KR20200110576A (ko) * | 2019-03-15 | 2020-09-24 | 재단법인대구경북과학기술원 | 사이토카인 기반 면역세포 및 그의 면역 치료 용도 |
| EP3712257A1 (en) * | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| MX2021011373A (es) * | 2019-03-21 | 2022-01-06 | Onk Therapeutics Ltd | Celulas efectoras inmunitarias modificadas con mayor resistencia a la muerte celular. |
| CN110079529A (zh) * | 2019-04-28 | 2019-08-02 | 成都美杰赛尔生物科技有限公司 | 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途 |
| CN110106202A (zh) * | 2019-05-07 | 2019-08-09 | 杭州师范大学 | 抗肿瘤nk细胞的制备方法及其细胞与应用 |
| EP3982983A4 (en) * | 2019-06-14 | 2023-11-15 | G Tech Bio LLC | ACTIVATED LYMPHOCYTES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES |
| CN110205293A (zh) * | 2019-06-25 | 2019-09-06 | 中冠赛尔生物科技(北京)有限公司 | 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用 |
| US20210077527A1 (en) * | 2019-09-13 | 2021-03-18 | The Research Institute At Nationwide Children's Hospital | Universal donor selection method to identify nk-cell-donors |
| WO2021051088A1 (en) * | 2019-09-13 | 2021-03-18 | Ohio State Innovation Foundation | Nk cell immunotherapy compositions, methods of making and methods of using same |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| AU2020437669A1 (en) | 2020-03-26 | 2022-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CD28H domain-containing chimeric antigen receptors and methods of use |
| WO2022007796A1 (zh) * | 2020-07-06 | 2022-01-13 | 上海鑫湾生物科技有限公司 | 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用 |
| EP3964265A1 (en) * | 2020-09-07 | 2022-03-09 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof |
| CN112029721A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | 一种活性增强型nk细胞的制备方法 |
| KR102581230B1 (ko) * | 2020-10-16 | 2023-09-21 | 의료법인 성광의료재단 | 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도 |
| CN116802273A (zh) | 2020-11-04 | 2023-09-22 | 美国政府(由卫生和人类服务部的部长所代表) | Ccr5表达减少的经修饰的nk细胞及其使用方法 |
| CN115505572B (zh) * | 2021-06-22 | 2025-11-14 | 康立泰生物医药(青岛)有限公司 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
| AU2022337186A1 (en) * | 2021-08-30 | 2025-03-06 | Carrygenes Bioengineering, Llc | Use of chemokine receptors in cellular homing |
| WO2023044304A1 (en) | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| CN114306606B (zh) * | 2021-11-29 | 2023-05-26 | 江苏省人民医院（南京医科大学第一附属医院） | cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用 |
| CN114381434A (zh) * | 2022-01-17 | 2022-04-22 | 华东师范大学 | 一种趋化型car-nk细胞及其制备方法和应用 |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
| CN115074325A (zh) * | 2022-07-07 | 2022-09-20 | 广州希灵生物科技有限公司 | Herceptin联合4-1BBL体外扩增NK方法 |
| CN115466726B (zh) * | 2022-09-05 | 2023-09-19 | 北京景达生物科技有限公司 | 一种nk细胞的高效基因转导方案 |
| CN116178566A (zh) * | 2022-09-30 | 2023-05-30 | 深圳博雅感知药业有限公司 | 靶向cd33的嵌合抗原受体和制备b16-cd33 car-nk细胞的方法 |
| CN115975922B (zh) * | 2022-12-15 | 2024-06-28 | 杭州师范大学 | Bx795在制备nk-92细胞激活剂上的应用 |
| CN120344655A (zh) * | 2022-12-19 | 2025-07-18 | 苏州沙砾生物科技有限公司 | 一种细胞培养方法及其用途 |
| WO2024261045A1 (en) | 2023-06-20 | 2024-12-26 | Zelluna Immunotherapy As | Methods of enhancing or modifying nk cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| DE10019075B4 (de) * | 2000-04-18 | 2007-01-18 | Vision 7 Gmbh | Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20090104170A1 (en) | 2004-11-02 | 2009-04-23 | Richard William Wyatt Childs | Compositions and methods for treating hyperproliferative disorders |
| CN101356679A (zh) * | 2005-10-31 | 2009-01-28 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物和方法 |
| US20070264687A1 (en) * | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| CN101684456A (zh) * | 2008-09-28 | 2010-03-31 | 江门罗森生物制药有限公司 | 一种体外培养条件下扩增人nk细胞的方法 |
| US10316333B2 (en) * | 2009-06-17 | 2019-06-11 | Tocagen Inc. | Producer cells for replication competent retroviral vectors |
| CN104853766A (zh) * | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| EP2793026A1 (en) * | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| EP2992020B1 (en) * | 2013-05-03 | 2020-01-15 | Ohio State Innovation Foundation | Cs1-specific chimeric antigen receptor engineered immune effector cells |
| US20170029777A1 (en) * | 2014-01-27 | 2017-02-02 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| US10813952B2 (en) | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| WO2016085946A1 (en) * | 2014-11-24 | 2016-06-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Active cxcr4+ immune cells and methods for their production and use |
| DK3356524T3 (da) * | 2015-09-30 | 2021-11-15 | Vycellix Inc | Forøget genlevering til naturlige dræberceller, hæmatopoietiske stamceller og makrofager |
| CN105567634A (zh) * | 2016-01-27 | 2016-05-11 | 上海润泉生物技术有限公司 | 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法 |
| CN109844099B (zh) | 2016-07-25 | 2024-01-02 | 美国政府(由卫生和人类服务部的部长所代表) | 产生经修饰的自然杀伤细胞的方法及使用方法 |
| US20200392457A1 (en) * | 2016-07-25 | 2020-12-17 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
| CN106350487B (zh) * | 2016-09-13 | 2019-01-25 | 北京多赢时代转化医学研究院 | 联合制备car-nk细胞和car-nkt细胞的方法 |
| US11058752B2 (en) * | 2016-11-22 | 2021-07-13 | Alloplex Biotherapeutics | Allogeneic tumor cell vaccine |
-
2017
- 2017-07-25 CN CN201780046354.1A patent/CN109844099B/zh active Active
- 2017-07-25 JP JP2019503538A patent/JP7086928B2/ja active Active
- 2017-07-25 SG SG11201810871WA patent/SG11201810871WA/en unknown
- 2017-07-25 WO PCT/US2017/043774 patent/WO2018022646A1/en not_active Ceased
- 2017-07-25 EP EP17754517.5A patent/EP3487991B1/en active Active
- 2017-11-01 US US15/801,085 patent/US11293010B2/en active Active
-
2018
- 2018-11-01 SG SG11202003201QA patent/SG11202003201QA/en unknown
- 2018-11-01 EP EP18811415.1A patent/EP3704231A1/en active Pending
- 2018-11-01 CN CN201880071474.1A patent/CN111344395B/zh active Active
- 2018-11-01 WO PCT/US2018/058747 patent/WO2019089955A1/en not_active Ceased
- 2018-11-01 IL IL273979A patent/IL273979B2/en unknown
- 2018-11-01 JP JP2020524196A patent/JP7364559B2/ja active Active
-
2022
- 2022-03-07 US US17/688,435 patent/US12448604B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523001A5 (enExample) | ||
| JP2021501578A5 (enExample) | ||
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| IL273979B2 (en) | Methods of producing modified natural killer cells and methods of use | |
| JP2022130607A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| Murad et al. | Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy | |
| Meng et al. | Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells | |
| JP2022549303A (ja) | 免疫細胞を拡大増殖するためのｃｂｌ阻害剤および組成物 | |
| CN118813544A (zh) | 遗传修饰的自然杀伤细胞 | |
| Zhang et al. | Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS− regulatory T cells | |
| JP6971986B2 (ja) | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 | |
| JP2022542321A (ja) | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 | |
| Shook et al. | Natural killer cell engineering for cellular therapy of cancer | |
| CN115768879A (zh) | 用于培养细胞的方法 | |
| Xu et al. | Cellular immunotherapy for hematological malignancy: recent progress and future perspectives | |
| CN113785048B (zh) | 用于扩增和分化在过继转移疗法中的t淋巴细胞和nk细胞的方法 | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| JPWO2007105797A1 (ja) | 新規なヒトｔ細胞集団 | |
| Ye et al. | Folate Receptor‐Alpha Targeted 7x19 CAR‐γδT Suppressed Triple‐Negative Breast Cancer Xenograft Model in Mice | |
| JP2018531016A5 (enExample) | ||
| Li et al. | Emerging trends in clinical allogeneic CAR cell therapy | |
| Han et al. | Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies | |
| Deiser et al. | Interleukin-7 modulates anti-tumor CD8+ T cell responses via its action on host cells |